About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: IPXL
- CUSIP: 45256B10
- Previous Close: $14.70
- 50 Day Moving Average: $13.25
- 200 Day Moving Average: $18.26
- 52-Week Range: $11.65 - $37.20
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 10.35
- P/E Growth: 0.89
- Market Cap: $1.03B
- Outstanding Shares: 71,330,000
- Beta: 1.32
- Net Margins: -19.93%
- Return on Equity: 11.34%
- Return on Assets: 5.99%
Companies Related to Impax Laboratories:
- Debt-to-Equity Ratio: 0.90%
- Current Ratio: 2.09%
- Quick Ratio: 1.59%
What is Impax Laboratories' stock symbol?
Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."
Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?
15 brokers have issued 1 year target prices for Impax Laboratories' shares. Their forecasts range from $15.00 to $48.00. On average, they expect Impax Laboratories' stock price to reach $26.43 in the next year.
When will Impax Laboratories announce their earnings?
Impax Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
What are analysts saying about Impax Laboratories stock?
Here are some recent quotes from research analysts about Impax Laboratories stock:
According to Zacks Investment Research, "The acquisitions of Tower and Lineage boosted Impax’s branded and generics portfolio. Impax’s generics pipeline should be able to take advantage of the upcoming patent expiries in the pharma industry. The acquisition of several generic products in Aug 2016 further added 18 generic products to the company’s portfolio including 15 currently marketed products thus boding positive for the company. However, Impax’s Generics segment has been under competitive pressure for Solaraze and Skelaxin, as well as due to lower sales of Adderall XR. Moreover, short-term Albenza supply interruption has impacted results at the Specialty segment. Estimates have been declining ahead of company’s Q4 results. Shares of Impax have underperformed the Generics-Drugs industry in the past one year. " (1/17/2017)
- BMO Capital Markets analysts commented, "an opportunistic one for IPXL and could drive some upside to our Adrenaclick forecasts." (1/13/2017)
Who owns Impax Laboratories stock?
Impax Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (2.51%), Renaissance Technologies LLC (1.53%), Two Sigma Investments LP (1.49%), NWQ Investment Management Company LLC (1.44%), FMR LLC (0.57%) and Federated Investors Inc. PA (0.40%). Company insiders that own Impax Laboratories stock include Leslie Z Benet, Mark A Schlossberg, Michael Markbreiter, Michael Nestor and Peter R Terreri.
Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?
Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, FMR LLC, Thrivent Financial for Lutherans, NWQ Investment Management Company LLC, Pacad Investment Ltd., AQR Capital Management LLC and GSA Capital Partners LLP.
Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?
Impax Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Renaissance Technologies LLC, Federated Investors Inc. PA, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, Lyon Street Capital LLC, Tudor Investment Corp Et Al and Menta Capital LLC.
How do I buy Impax Laboratories stock?
Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Impax Laboratories stock cost?
One share of Impax Laboratories stock can currently be purchased for approximately $14.70.